On the contrary, Cappelli et al. studied 150 patients with NPM1 mutant (mut) AML in remission and suggested that IDH1, IDH2, SRSF2, and DTA mutations could be considered together as CHIP-like mutations and did not adversely affect the prognosis. This evidence concerns the gene IDH2 and acute myeloid leukemia.